CA1283356C - Composes pharmaceutiques d'interleukine-2 produite par des microorganismes - Google Patents

Composes pharmaceutiques d'interleukine-2 produite par des microorganismes

Info

Publication number: CA1283356C
Authority: CA; Canada
Prior art keywords: recombinant; microbially produced; mixture; per; selectively oxidized
Prior art date: 1985-09-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA000490072A

Other languages

English (en)

Inventor

Peter Fernandes

Terrance Taforo

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis Vaccines and Diagnostics Inc

Original Assignee

Cetus Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-09-05

Filing date

1985-09-05

Publication date

1991-04-23

1985-09-05 Application filed by Cetus Corp filed Critical Cetus Corp

1985-09-05 Priority to CA000490072A priority Critical patent/CA1283356C/fr

1991-04-23 Application granted granted Critical

1991-04-23 Publication of CA1283356C publication Critical patent/CA1283356C/fr

2008-04-23 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

108010002350 Interleukin-2 Proteins 0.000 title claims abstract description 120
102000000588 Interleukin-2 Human genes 0.000 title claims description 116
239000008194 pharmaceutical composition Substances 0.000 title claims description 12
239000000203 mixture Substances 0.000 claims abstract description 40
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims abstract description 21
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
239000007924 injection Substances 0.000 claims abstract description 12
238000002347 injection Methods 0.000 claims abstract description 12
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 10
229930195725 Mannitol Natural products 0.000 claims abstract description 10
239000000594 mannitol Substances 0.000 claims abstract description 10
235000010355 mannitol Nutrition 0.000 claims abstract description 10
238000007911 parenteral administration Methods 0.000 claims abstract description 4
239000000243 solution Substances 0.000 claims description 24
238000002560 therapeutic procedure Methods 0.000 claims description 13
239000008174 sterile solution Substances 0.000 claims description 8
239000004094 surface-active agent Substances 0.000 claims description 4
230000002411 adverse Effects 0.000 claims description 3
239000003981 vehicle Substances 0.000 claims description 3
239000008135 aqueous vehicle Substances 0.000 claims description 2
229960003964 deoxycholic acid Drugs 0.000 claims description 2
230000002209 hydrophobic effect Effects 0.000 claims description 2
239000008215 water for injection Substances 0.000 claims description 2
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims 1
238000000034 method Methods 0.000 abstract description 12
238000009472 formulation Methods 0.000 abstract description 10
239000012931 lyophilized formulation Substances 0.000 abstract 1
235000018102 proteins Nutrition 0.000 description 28
108090000623 proteins and genes Proteins 0.000 description 28
102000004169 proteins and genes Human genes 0.000 description 28
238000004007 reversed phase HPLC Methods 0.000 description 17
238000000605 extraction Methods 0.000 description 16
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 14
241000588724 Escherichia coli Species 0.000 description 12
210000004027 cell Anatomy 0.000 description 12
238000002523 gelfiltration Methods 0.000 description 12
244000005700 microbiome Species 0.000 description 11
239000002904 solvent Substances 0.000 description 11
150000001413 amino acids Chemical class 0.000 description 10
239000000047 product Substances 0.000 description 10
238000011282 treatment Methods 0.000 description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
235000018417 cysteine Nutrition 0.000 description 9
239000003638 chemical reducing agent Substances 0.000 description 8
230000002829 reductive effect Effects 0.000 description 8
239000000356 contaminant Substances 0.000 description 7
230000003211 malignant effect Effects 0.000 description 7
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
239000007864 aqueous solution Substances 0.000 description 6
239000000872 buffer Substances 0.000 description 6
230000001413 cellular effect Effects 0.000 description 6
230000003647 oxidation Effects 0.000 description 6
238000007254 oxidation reaction Methods 0.000 description 6
238000005063 solubilization Methods 0.000 description 6
230000007928 solubilization Effects 0.000 description 6
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
150000001945 cysteines Chemical group 0.000 description 5
239000003599 detergent Substances 0.000 description 5
239000000463 material Substances 0.000 description 5
239000002609 medium Substances 0.000 description 5
239000012071 phase Substances 0.000 description 5
239000007790 solid phase Substances 0.000 description 5
235000001014 amino acid Nutrition 0.000 description 4
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
239000001963 growth medium Substances 0.000 description 4
102000055277 human IL2 Human genes 0.000 description 4
230000006698 induction Effects 0.000 description 4
230000007935 neutral effect Effects 0.000 description 4
239000003960 organic solvent Substances 0.000 description 4
230000008569 process Effects 0.000 description 4
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 3
208000035473 Communicable disease Diseases 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
230000005526 G1 to G0 transition Effects 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
239000000427 antigen Substances 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
239000012062 aqueous buffer Substances 0.000 description 3
BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
239000004202 carbamide Substances 0.000 description 3
LEVWYRKDKASIDU-IMJSIDKUSA-N cystine group Chemical group C([C@@H](C(=O)O)N)SSC[C@@H](C(=O)O)N LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
229960001484 edetic acid Drugs 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000002158 endotoxin Substances 0.000 description 3
239000000499 gel Substances 0.000 description 3
239000007791 liquid phase Substances 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
239000013618 particulate matter Substances 0.000 description 3
239000001488 sodium phosphate Substances 0.000 description 3
229910000162 sodium phosphate Inorganic materials 0.000 description 3
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
208000025747 Rheumatic disease Diseases 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
GONSYFXEPMZGNN-UHFFFAOYSA-N acetic acid;propan-1-ol Chemical compound CCCO.CC(O)=O GONSYFXEPMZGNN-UHFFFAOYSA-N 0.000 description 2
PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
229910052783 alkali metal Inorganic materials 0.000 description 2
229910052936 alkali metal sulfate Inorganic materials 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
230000003416 augmentation Effects 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000003196 chaotropic effect Effects 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
229960003067 cystine Drugs 0.000 description 2
238000011026 diafiltration Methods 0.000 description 2
239000003814 drug Substances 0.000 description 2
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
238000000265 homogenisation Methods 0.000 description 2
230000002519 immonomodulatory effect Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
229940047124 interferons Drugs 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
238000002156 mixing Methods 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
IFPHDUVGLXEIOQ-UHFFFAOYSA-N ortho-iodosylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I=O IFPHDUVGLXEIOQ-UHFFFAOYSA-N 0.000 description 2
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
ZIHBOROHTYWINY-UHFFFAOYSA-N propan-1-ol;2,2,2-trifluoroacetic acid Chemical compound CCCO.OC(=O)C(F)(F)F ZIHBOROHTYWINY-UHFFFAOYSA-N 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000001698 pyrogenic effect Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
230000003381 solubilizing effect Effects 0.000 description 2
238000000527 sonication Methods 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
241001646716 Escherichia coli K-12 Species 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
101100232904 Homo sapiens IL2 gene Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
101150083678 IL2 gene Proteins 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
102100037850 Interferon gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
108010002386 Interleukin-3 Proteins 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
108010089814 Plant Lectins Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
239000008156 Ringer's lactate solution Substances 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
239000012506 Sephacryl® Substances 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
241000209140 Triticum Species 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
239000006035 Tryptophane Substances 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000003916 acid precipitation Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
238000007792 addition Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
230000004075 alteration Effects 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000002022 anti-cellular effect Effects 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
230000000842 anti-protozoal effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000002585 base Substances 0.000 description 1
238000010923 batch production Methods 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
239000004067 bulking agent Substances 0.000 description 1
BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
238000011210 chromatographic step Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
230000001351 cycling effect Effects 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
238000011393 cytotoxic chemotherapy Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
239000003398 denaturant Substances 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
239000008355 dextrose injection Substances 0.000 description 1
238000010586 diagram Methods 0.000 description 1
238000007865 diluting Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000000539 dimer Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
-1 energy sources Chemical compound 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000005187 foaming Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
238000001641 gel filtration chromatography Methods 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
201000005787 hematologic cancer Diseases 0.000 description 1
208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
239000012510 hollow fiber Substances 0.000 description 1
210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
230000008348 humoral response Effects 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
210000003000 inclusion body Anatomy 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000012933 kinetic analysis Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
230000021633 leukocyte mediated immunity Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910001425 magnesium ion Inorganic materials 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000003607 modifier Substances 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
239000003791 organic solvent mixture Substances 0.000 description 1
230000003071 parasitic effect Effects 0.000 description 1
239000003726 plant lectin Substances 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910001414 potassium ion Inorganic materials 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
230000000552 rheumatic effect Effects 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
229910001415 sodium ion Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000005062 synaptic transmission Effects 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
229960004799 tryptophan Drugs 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Landscapes

Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA000490072A 1985-09-05 1985-09-05 Composes pharmaceutiques d'interleukine-2 produite par des microorganismes Expired - Lifetime CA1283356C (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA000490072A CA1283356C (fr)	1985-09-05	1985-09-05	Composes pharmaceutiques d'interleukine-2 produite par des microorganismes

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA000490072A CA1283356C (fr)	1985-09-05	1985-09-05	Composes pharmaceutiques d'interleukine-2 produite par des microorganismes

Publications (1)

Publication Number	Publication Date
CA1283356C true CA1283356C (fr)	1991-04-23

Family

ID=4131318

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000490072A Expired - Lifetime CA1283356C (fr)	1985-09-05	1985-09-05	Composes pharmaceutiques d'interleukine-2 produite par des microorganismes

Country Status (1)

Country	Link
CA (1)	CA1283356C (fr)

1985
- 1985-09-05 CA CA000490072A patent/CA1283356C/fr not_active Expired - Lifetime

Legal Events

Date	Code	Title	Description
2008-04-23	MKEX	Expiry

Publication	Publication Date	Title
US4604377A (en)	1986-08-05	Pharmaceutical compositions of microbially produced interleukin-2
EP0268110B1 (fr)	1992-04-08	Compositions pharmaceutiques d'interleukine-2 recombinante et procédés de préparation
EP0217645B1 (fr)	1991-09-04	Formulation stable de protéines biologiquement actives pour l'injection parentérale
EP0206828B1 (fr)	1992-02-26	Procédé de récupération de corps réfractants contenant des protéines hétérologues à partir d'hôtes microbiens et son application
EP0357645B1 (fr)	1997-05-07	Procede ameliore de recuperation d'interleukine-2 produite de maniere microbienne
EP0211835B1 (fr)	1990-01-03	Compositions pharmaceutiques d'interleucine-2 produite par voie microbienne
US5004605A (en)	1991-04-02	Low pH pharmaceutical compositions of recombinant β-interferon
EP0215658B1 (fr)	1994-06-01	Formulation pour l'interféron bêta recombinant, procédés pour la récupération et la stabilisation de l'interféron bêta et son application
US5037644A (en)	1991-08-06	Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
EP0270799A1 (fr)	1988-06-15	Compositions pharmaceutiques de bêta-interféron recombinant et procédés de préparation
EP0470586A1 (fr)	1992-02-12	Compositions contenant de l'interleukine-2 recombinante purifiée
CA1295087C (fr)	1992-01-28	PURIFICATION DU .beta.-INTERFERON RECOMBINANT PAR CLHP A PHASES INVERSEES
US5643566A (en)	1997-07-01	Formulation processes for lipophilic proteins
US5162507A (en)	1992-11-10	Process for recovering purified, oxidized, renatured recombinant interleukin-2 from microorganisms
EP0368857B1 (fr)	1997-08-06	Procede de recuperation, a partir de microorganismes, d'interleukine-2 recombinante, purifiee, oxydee et renaturee
JP3016793B2 (ja)	2000-03-06	還元型の非グリコシル化組換ヒトｉｌ▲下２▼、その取得方法、及び薬物としてのその使用
CA1283356C (fr)	1991-04-23	Composes pharmaceutiques d'interleukine-2 produite par des microorganismes
CA1337671C (fr)	1995-11-28	Procede de recuperation de l'interleukin-2 recombinante, oxydee, renaturee et purifiee a partir de microorganismes
BG60405B2 (bg)	1995-02-28	Фармацевтични състави от микробно произведен интерлевкин-2
HK1004474B (en)	2000-03-17	Purified recombinant interleukin-2 compositions